ReviewBiochimie2017
PPARs and nonalcoholic fatty liver disease.
Review in Biochimie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2025Pooled it
- Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.International journal of molecular sciences · 2024Pooled it
- Fatty acid composition but not quantity is an important indicator of non-alcoholic fatty liver disease: a systematic review.European journal of clinical nutrition · 2023Pooled it
- Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study.Frontiers in medicine · 2021Pooled it
- Six-compound cocktail for maturation of human pluripotent stem cell-derived liver spheroids for toxicity prediction.Nature communications · 2026Article
- Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives.Metabolites · 2026Review
- The roles of free-fatty acid receptors in the pathophysiology of renal disorders.The Journal of pharmacology and experimental therapeutics · 2026Review
- Present and Future Perspectives in the Treatment of Liver Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Loss of endothelial ZEB2 in mice attenuates steatosis early during metabolic dysfunction-associated steatotic liver disease.Scientific reports · 2025Article
- Combined effects of IRAK inhibition and pioglitazone on hepatic inflammation and apoptosis in a mouse model of MASLD.Molecular biology reports · 2025Article
- A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model.Scientific reports · 2025Article
- Hepatoprotective and Antiatherosclerotic Effects of Oleoylethanolamide-Based Dietary Supplement in Dietary-Induced Obesity in Mice.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Ginkgolide C attenuated Western diet-induced non-alcoholic fatty liver disease via increasing AMPK activation.Inflammation · 2025Article
- The Therapeutic Potential of Orange Juice in Cardiac Remodeling: A Metabolomics Approach.Metabolites · 2025Article
- Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities.Cell & bioscience · 2025Article
- Integrating Gut Microbiome and Metabolome to Gain Insight into Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastro hep advances · 2025Article
- Genomic Exploration of Nonalcoholic Fatty Liver Disease: Insights From Gene Expression and Variation in Morbidly Obese Individuals.Journal of obesity · 2025Article
- Advancements in the understanding of mechanisms of the IL-6 family in relation to metabolic-associated fatty liver disease.Frontiers in endocrinology · 2025Review
- Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis. Without intervention it can progress to end-stage liver disease and hepatocellular carcinoma. Given its close association with obesity, the prevalence of NAFLD has increased dramatically worldwide. Currently, there are no FDA-approved medications for the treatment of NAFLD and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients. As such, the search for effective therapeutic agents is an active area of research. Peroxisome proliferator-activated receptors (PPARs) belong to a class of nuclear receptors. Because of their key role in the transcriptional regulation of mediators of glucose and lipid metabolism, PPAR ligands have been investigated as possible therapeutic agents. Here we review the current evidence from preclinical and clinical studies investigating the therapeutic potential of PPAR ligands for the treatment of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.